TY - JOUR
T1 - Development of EPAT
T2 - An assessment tool for pediatric hematology/oncology training programs
AU - Moreira, Daniel C
AU - Metzger, Monika L
AU - Antillón-Klussmann, Federico
AU - González-Ramella, Oscar
AU - Gao, Yijin
AU - Bazzeh, Faiha
AU - Middlekauff, Janet
AU - Fox Irwin, Leeanna
AU - Gonzalez, Miriam L
AU - Chantada, Guillermo
AU - Barr, Ronald D
AU - Garrington, Timothy
AU - Hastings, Caroline
AU - Kutluk, Tezer
AU - Saab, Raya
AU - Khan, Muhammad Saghir
AU - Saha, Vaskar
AU - Rodríguez-Galindo, Carlos
AU - Friedrich, Paola
N1 - © 2023 American Cancer Society.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - PURPOSE: In the absence of a standardized tool to assess the quality of pediatric hematology/oncology training programs, the Education Program Assessment Tool (EPAT) was conceptualized as a user-friendly and adaptable tool to evaluate and identify areas of opportunity, pinpoint needed modifications, and monitor progress for training programs around the world.METHODS: The development of EPAT consisted of three main phases: operationalization, consensus, and piloting. After each phase, the tool was iteratively modified based on feedback to improve its relevance, usability, and clarity.RESULTS: The operationalization process led to the development of 10 domains with associated assessment questions. The two-step consensus phase included an internal consensus phase to validate the domains and a subsequent external consensus phase to refine the domains and overall function of the tool. EPAT domains for programmatic evaluation are hospital infrastructure, patient care, education infrastructure, program basics, clinical exposure, theory, research, evaluation, educational culture, and graduate impact. EPAT was piloted in five training programs in five countries, representing diverse medical training and patient care contexts for proper validation of the tool. Face validity was confirmed by a correlation between the perceived and calculated scores for each domain (r = 0.78, p < .0001).CONCLUSIONS: EPAT was developed following a systematic approach, ultimately leading to a relevant tool to evaluate the different core elements of pediatric hematology/oncology training programs across the world. With EPAT, programs will have a tool to quantitatively evaluate their training, allowing for benchmarking with centers at the local, regional, and international level.
AB - PURPOSE: In the absence of a standardized tool to assess the quality of pediatric hematology/oncology training programs, the Education Program Assessment Tool (EPAT) was conceptualized as a user-friendly and adaptable tool to evaluate and identify areas of opportunity, pinpoint needed modifications, and monitor progress for training programs around the world.METHODS: The development of EPAT consisted of three main phases: operationalization, consensus, and piloting. After each phase, the tool was iteratively modified based on feedback to improve its relevance, usability, and clarity.RESULTS: The operationalization process led to the development of 10 domains with associated assessment questions. The two-step consensus phase included an internal consensus phase to validate the domains and a subsequent external consensus phase to refine the domains and overall function of the tool. EPAT domains for programmatic evaluation are hospital infrastructure, patient care, education infrastructure, program basics, clinical exposure, theory, research, evaluation, educational culture, and graduate impact. EPAT was piloted in five training programs in five countries, representing diverse medical training and patient care contexts for proper validation of the tool. Face validity was confirmed by a correlation between the perceived and calculated scores for each domain (r = 0.78, p < .0001).CONCLUSIONS: EPAT was developed following a systematic approach, ultimately leading to a relevant tool to evaluate the different core elements of pediatric hematology/oncology training programs across the world. With EPAT, programs will have a tool to quantitatively evaluate their training, allowing for benchmarking with centers at the local, regional, and international level.
U2 - 10.1002/cncr.34946
DO - 10.1002/cncr.34946
M3 - Article
C2 - 37417913
SN - 0008-543X
VL - 129
SP - 3448
EP - 3456
JO - Cancer
JF - Cancer
IS - 21
ER -